Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study

Amiaz, Revital; Fostick, Leah; Gershon, Ari A.; Zohar, Joseph

doi:10.1016/j.euroneuro.2008.01.006

Cited by 54 publications

(35 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one patient on morphine showed sufficient response (Koran et al 2005a)(C2). Á In a small DBPC cross-over study with 10 treatment-refractory patients, the opioid antagonist naltrexone did not improve OCD symptoms, but even led to and exacerbation of anxiety and depression (Amiaz et al 2008)(E). Á In a DBPC study, a statistically significant reduction in symptoms was noted after lithium augmentation of ongoing fluvoxamine treatment, although most patients did not have a clinically meaningful response, according to the authors …”

Section: Treatment-resistantmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

Self Cite

711

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: Treatment-resistantmentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

Self Cite

711

410

View full text Add to dashboard Cite

show abstract

“…The opioid antagonist naltrexone, which has been used in many impulse control disorders, has not been found to be effective in OCD as an augmenting agent. Rather, it appears to increase dysphoria in people with OCD [97].…”

Section: Opioid Systemmentioning

confidence: 99%

Augmentation strategies in obsessive–compulsive disorder

Arumugham

Reddy

2013

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

“…Unlike this meta-analysis that looked at differences in outcome for different symptoms of OCD, our meta-analysis aimed to focus on pharmacotherapeutic trials that specifically assessed outcome for pathological hoarding (regardless of whether or not it occurs in the context of OCD). Studies assessing pharmacotherapy for hoarding are lacking in general with only one published randomized control trial (Amiaz et al, 2008). Reviews have also tended to assess the pharmacotherapy of hoarding within the context of OCD with studies reporting mixed results regarding the response of hoarding symptoms to pharmacotherapy in comparison to other OCD symptoms (Starcevic and Brakoulias, 2008).…”

Section: Introductionmentioning

confidence: 99%